Remicade biosimilar launched in UK Market

Biogen has launched its biosimilar version of Johnson & Johnson’s Remicade in the United Kingdom. Biogen’s biosimilar is the third copycat version of the drug to hit the market. Biogen’s version of the drug is named Flixabi, while Pfizer’s is named Inflectra and Mundipharma’s version is called Remsima. Remicade is approved to treat Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and psoriasis.

Read the source article at PMLive